Highlight
Unselected germline multigene testing in ovarian carcinoma identifies pathogenic/likely-pathogenic variants in nearly 30% of patients.
BRCA1/2 mutations remain predominant but significant detection extends beyond these genes, underscoring broader genetic assessment.
Germline and somatic BRCA testing show high concordance, facilitating complementary diagnostic strategies.
Optimized testing workflows balancing germline-first and tumor-first approaches enhance detection rates and reduce assay burden.
